Objective: Age-adjusted evaluations have explored the possible utility of human papillomavirus (HPV) test results in women with low-grade squamous intra-epithelial lesion (LSIL) Paps. We document LSIL correlation data with HPV test results and histopathologic follow-up from a large academic women’s hospital practice. Study Design: LSIL Pap tests with intermediate-/high-risk HPV DNA testing between July 1, 2005 and April 30, 2008 were studied along with follow-up histopathologic diagnoses. Patients were divided into age groups, and tissue diagnoses were correlated with HPV test results. Results: 1,083 (80.2%) of a total of 1,351 LSIL Pap samples tested HPV positive. HPV prevalence declined in older age groups. 719 women with LSIL Pap and HPV test results had at least 1 follow-up cervical biopsy result. 89 of 612 patients with HPV-positive LSIL (14.5%) had a follow-up histopathological diagnosis of cervical intra-epithelial neoplasia (CIN) 2/3. Only 4 of 107 patients with HPV-negative LSIL (3.7%) had CIN 2/3. Conclusions: In the largest study to date to document histopathological follow-up of older women with LSIL and HPV test results, no histopathological CIN 2/3 diagnoses were identified in women 50 years and older with HPV-negative LSIL. HPV test results stratified women with LSIL cytology findings into lower- and higher-risk groups for follow-up histopathologic CIN 2/3 outcomes.

Keywords:
Low-grade squamous intra-epithelial lesion, Human papillomavirus, Histopathologic follow-up, Gynecologic cytology, Older women
1.
Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ: ASCCP Sponsored Consensus Conference. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities (2001 ASCCP sponsored Consensus Conference). JAMA 2002;287:2120–2129.
2.
American College of Obstetricians and Gynecologists: Routine cancer screening. ACOG Committee Opinion No. 356. Obstet Gynecol 2006;108:1611–1613.
3.
Solomon D, Breen N, McNeel T: Cervical cancer screening rates in the United States and the potential impact of implementation of screening guidelines. CA Cancer J Clin 2007;57:105–111.
4.
The Atypical Squamous Cells of Undetermined Significance/Low Grade Squamous Intraepithelial Lesions Triage Study: Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000;92:397–402.
5.
Sherman ME, Schiffman M, Cox TJ: Effects of age and human papilloma viral load on colposcopy triage: data from the Randomized Atypical Squamous cells of Undetermined Significance/Low-Grade Squamous Intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst 2002;94:102–107.
6.
Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: 2006 Consensus guidelines for the management of women with abnormal cervical cancer screening tests (2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference). Am J Obstet Gynecol 2007;197:346–355.
7.
Ronco G, Cuzick J, Segnan N, Brezzi S, Carozzi F, Folicaldi S, et al: HPV triage for low grade (LSIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid-based cytology. Eur J Cancer 2007;43:476–480.
8.
Wright TC, Schiffman M: Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003;348:489–490.
9.
2006 US Census Bureau: American Community Survey. www.census.gov/acs/www (accessed June 23, 2009).
10.
de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX: Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453–459.
11.
Miller AB: The (in)efficiency of cervical screening in Europe. Eur J Cancer 2002;38:321–326.
12.
ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists: management of abnormal cervical cytology and histology. Obstet Gynecol 2008;112:1419–1444.
13.
Solomon D, Nayar R: The Bethesda System for Reporting Cervical Cytology, ed 2. New York, Springer, 2004.
14.
Dziura B, Quinn S, Richard K: Performance of an Imaging system vs. manual screening in the detection of squamous intraepithelial lesions of the cervix. Acta Cytol 2006;50:309–311.
15.
Zhao C, Austin RM: Human papillomavirus DNA detection in ThinPrep Pap test vials is independent of cytologic sampling of the transformation zone Gynecol Oncol 2007;107:231–235.
16.
Zhao C, Elishaev E , Yuan KH, Yu J, Austin RM: Very low human papillomavirus DNA prevalence in mature women with negative computer-imaged liquid-based Pap tests. Cancer (Cytopathol) 2007;111:292–297.
17.
Davey DD, Neal MH, Wilbur DC, Colgan TJ, Styer PE, Mody DR: Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med 2004;128:1224–1229.
18.
Hutchinson ML, Isenstein LM, Goodman A, Hurley AA, Douglass KL, Mui KK, et al: Homogeneous sampling accounts for the increase diagnostic accuracy using the ThinPrep Processor. Am J Clin Pathol 1994;10:215–219.
19.
Grohs HK, Zahnheiser DH, Geyer JW: Standardization of specimen preparation through mono/thinlayer technology; in Grohs HK, Husain OAN (eds): Automated Cervical Cancer Screening. New York, Igaku-Shouin, 1994, pp 176–185.
20.
Sherman ME, Wang SE, Tarone R, Rich L, Schiffman M: Histopathologic extent of cervical intraepithelial neoplasia 3 lesions in the atypical squamous cells of undetermined significance low-grade squamous intraepithelial lesion triage study: implications for subject safety and lead-time bias. Cancer Epid Biom Prev 2003;12:372–379.
21.
Schiffman M, Solomon D: Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med 2003;127:946–949.
22.
Jones BA, Novis DA: Cervical biopsy-cytology correlation: a College of American Pathologists Q-Probes study of 22,439 correlations in 348 laboratories. Arch Pathol Lab Med 1996;120:523–531.
23.
Atkins KA, Jeronimo J, Stoler MH; ALTS Group: Description of patients with squamous cell carcinoma in the atypical squamous cells of undetermined significance/low grade squamous intraepithelial lesion triage study. Cancer 2006;108:212–221.
24.
Bofin AM, Nygård JF, Skare GB, Dybdahl BM, Westerhagen U, Sauer T, Papanicolaou smear history in women with low-grade cytology before cervical cancer diagnosis. Cancer 2007;111:210–216.
25.
Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J: Clinical utility of HPV DNA detection: triage of minor cervical lesions, follow-up of women treated for high grade CIN: an update of pooled evidence. Gynecol Oncol 2005;99(suppl 1):S7–S11.
26.
Thrall MJ, Smith DA, Mody DR: Women ≧30 years of age with low grade squmaous intraepithelial lesion (LSIL) have low positivity rates when cotested for high-risk human papillomavirus: should we reconsider HPV triage for LSIL in older women? Diagn Cytopathol 2010;38:407–412.
27.
Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006;24(suppl 3):S3/78–S3/89.
28.
ASCUS-LSIL Traige Study (ALTS) Group: Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:1383–1392.
29.
Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, et al.: Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006;98:765–774.
30.
Evans MF, Adamson CS, Papillo JL, St John TL, Leiman G, Cooper K: Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes. Cancer 2006;106:1054–1064.
31.
Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, et al: A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005;191:1808–1816.
32.
Kulasingam SL , Kim JJ, Lawrence WF, Mandelblat JS, Myers ER, Schiffman M, Solomon D, Goldie SJ: Cost-effectiveness analysis based on the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst 2006;98:92–100.
33.
Garamszegi C, Dennerstein L, Dudley E, Guthrie JR, Ryan M, Burger H: Menopausal status: subjectively and objectively defined. J Psychosom Obstet Gynaecol 1998;19:165–173.
34.
Burger H: The menopausal transition: endocrinology. J Sex Med 2008;5:2266–2273.
35.
Castle P: HPV testing for the triage of ASCUS and LSIL; principles and results. Twenty-fifth International Papillomavirus Conference, Malmo, Sweden. www.hpv2009.org/Programme%20at%20a%20Glance 090413.pdf
36.
Baak JP, Kruse AJ: Use of biomarkers in the evaluation of CIN grade and progression of early CIN. Meth Molec Med 2005;119:85–99.
37.
ASCUS-LSIL Traige Study (ALTS) Group: A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003;188:1393–1400.
38.
Jeronimo J, Schiffman M: Colposcopy at a crossroads. Am J Obstet Gynecol 2006;195:349–353.
39.
Wentzensen N, Schiffman M, Dunn ST, Zuna RE, Walker J, Allen RA, et al: Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. Int J Cancer 2009;124:964–969.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.